02 January 2022: Clinical Research
Retrospective Study of 573 Patients with Heart Failure Evaluated for Coronary Artery Disease at Toulouse University Center, France
Antoine Deney 1ABCDEF* , Vanessa Nader 12ABCDEF* , Anthony Matta 13ABCDE , Romain Itier 1CDE , Pauline Fournier 1ABCD , Olivier Lairez 1ADF , Nathalie Pizzinat 4ACD , Didier Carrié 1ACD , Frédéric Boal 4ACD , Michel Galinier 1ACD , Oksana Kunduzova 4ACD , Rania Azar 2ACD , Jerome Roncalli 14ABCDEFG*DOI: 10.12659/MSM.934804
Med Sci Monit 2022; 28:e934804
Table 3 Characteristics of heart failure with preserved ejection fraction (HFpEF) group stratified by the presence of coronary artery disease.
| HFpEF populationN=89 | No CADN=39 | Significant CADN=50 | P-value | |
|---|---|---|---|---|
| Age | 72.53±9.722 | 70.59±10.43 | 74.04±8.95 | 0.097 |
| Male sex | 63 (70.78%) | 21 (53.85%) | 42 (84.00%) | 0.002 |
| BMI | 27.65±6.56 | 27.99±7.66 | 27.39±5.63 | 0.668 |
| Atrial fibrillation | 25 (28.09%) | 14 (35.89%) | 11 (22.00%) | 0.148 |
| Chronic kidney disease | 45 (50.56%) | 18 (46.15%) | 27 (54.00%) | 0.538 |
| Dyslipidemia | 39 (43.82%) | 14 (35.89%) | 25 (50.00%) | 0.237 |
| Diabetes mellitus | 29 (32.58%) | 10 (25.64%) | 19 (38.00%) | 0.267 |
| Hypertension | 61 (68.54%) | 25 (61.10%) | 36 (72.00%) | 0.596 |
| Smoking | 11 (12.36%) | 3 (7.69%) | 8 (16.00%) | 0.338 |
| Family history | 11 (15.53%) | 4 (10.25%) | 7 (14.00%) | 0.751 |
| Valvopathy | 29 (32.58%) | 12 (30.77%) | 17 (34.00%) | 0.697 |
| Right ventricular dysfunction | 6 (6.74%) | 3 (7.69%) | 3 (6.00%) | 0.182 |
| TAPSE | 16.45±3.48 | 12.67±2.31 | 17.88±2.70 | 0.016 |
| PAPSE | 40.62±10.26 | 41.43±10.29 | 39.67±11.11 | 0.772 |
| Pacemaker | 6 (6.74%) | 0 | 6 (12.00%) | 0.033 |
| Defibrillator | 1 (1.12%) | 0 | 1 (2.00%) | 1 |
| NYHA class | ||||
| 1 | 0.115 | |||
| 2 | 17 (19.10%) | 4 (10.26%) | 13 (26.00%) | |
| 3 | 20 (22.47%) | 6 (15.38%) | 14 (28.00%) | |
| 4 | 4 (4.49%) | 3 (7.69%) | 1 (2.00%) | |
| Systolic blood pressure | 137.72±22.43 | 134.52±24.00 | 139.73±21.45 | 0.367 |
| Diastolic blood pressure | 72.92±20.56 | 71.48±29.31 | 73.83±12.76 | 0.658 |
| Heart rate | 77.91±17.95 | 83.48±14.39 | 74.43±19.21 | 0.047 |
| Troponin | 112.13±212.21 | 184.82±344.36 | 72.15±62.86 | 0.307 |
| NT-ProBNP | 4073.81±7245.54 | 4523.32±7943.45 | 3724.19±6747.79 | 0.665 |
| β-blockers | 41 (46.07%) | 17 (43.59%) | 24 (48.00%) | 0.679 |
| Diuretics | 50 (56.18%) | 21 (53.85%) | 29 (58.00%) | 0.695 |
| Mineralocorticoids | 11 (12.36%) | 4 (10.26%) | 7 (14.00%) | 0.749 |
| ACE/ARA | 51 (57.30%) | 24 (61.54%) | 27 (54.00%) | 0.476 |
| ARNI | 3 (3.37%) | 3 (7.69%) | 0 | 0.080 |
| SAPT | 36 (40.45%) | 11 (28.21%) | 25 (50.00%) | 0.031 |
| DAPT | 8 (8.98%) | 1 (2.56%) | 7 (14.00%) | 0.075 |
| DOAC+AVK | 27 (30.34%) | 11 (28.21%) | 16 (32.00%) | 0.699 |
| AAP+OAC | 6 (6.74%) | 1 (2.56%) | 5 (10.00%) | 0.225 |
| β-blockers | 58 (65.17%) | 26 (66.66%) | 32 (64.00%) | 0.894 |
| Diuretics | 62 (69.66%) | 25 (64.10%) | 37 (74.00%) | 0.314 |
| Mineralocorticoids | 19 (21.35%) | 9 (23.07%) | 10 (20.00%) | 0.725 |
| ACE/ARA | 65 (73.03%) | 28 (71.79%) | 37 (74.00%) | 0.816 |
| ARNI | 4 (4.49%) | 3 (7.69%) | 1 (2.00%)) | 0.315 |
| Ivabradine | 2 (2.23%) | 1 (2.56%) | 1 (2.00%) | 1 |
| SAPT | 33 (37.08%) | 11 (28.21%) | 22 (44.00%) | 0.126 |
| DAPT | 29 (32.58%) | 2 (5.13%) | 27 (54.00%) | |
| DOAC+AVK | 31 (37.87%) | 16 (34.83%) | 15 (38.43%) | 0.279 |
| AAP+OAC | 11 (14.31%) | 2 (12.36%) | 9 (14.67%) | 0.103 |
| BMI – body mass index; APT – single anti-platelet therapy; DAPT – dual anti-platelet therapy; DOAC – direct oral anti-coagulant; AP+OAC – anti-platelet +oral anti-coagulant. | ||||